Awareness of Nurses/nurse Midwives Regarding Magnesium Sulfate Administration to Pre-Eclamptic /Eclamptic Mothers

Aida Ahmed Fadlala¹, Rosa Khalil Mohammed Babikir²,³,4, Zeinab Taha Ali ²,³,⁴, Nazik Abdelwahab Gassmalla³,⁵

Abstract

Background: Hypertension is the most common medical problem encountered in pregnancy and remains an important cause of maternal, and fetal, morbidity and mortality. It complicates up to 15% of pregnant mothers and accounts for approximately a quarter of all antenatal admissions. The hypertensive disorders of pregnancy cover a spectrum of conditions, of which pre eclampsia poses the greatest potential risk and remains one of the most common causes of maternal death in the UK. The aim of the study is to examine the nurses/nurse midwives knowledge regarding Magnesium Sulfate administration to pre-eclamptic /eclamptic mothers. Materials and Methods, study design is a descriptive – cross sectional hospital based study, at Bhari Teaching Hospital, Saad Abualla, and Omdurman Maternity Hospital, Khartoum State, Sudan. Sample size is 50 nurses/nurse midwives who are working in obstetrical wards are all enrolled in this study as total coverage. Data collection technique and tools: structured interview questionnaire sheet was developed to assess the nurses/nurse midwives' knowledge regarding Magnesium Sulfate administration to pre-eclamptic /eclamptic mothers and parameters of monitoring the patient. Data processing and statistical analysis: Data were analyzed by using Statistical Package for Social Sciences program (SPSS). Validity and reliability of instruments: The instruments were pre-tested in the pilot study before final data collection for reliability. Ethical consideration: from Ethical Committees, general medical directors of selected hospitals and verbal agree from the nurses who are working in obstetric wards.

Keywords: Nurses, nurse midwives, Magnesium Sulfate, knowledge, parameters

1. Introduction

1.1. Background:

Pre-eclampsia (PE) is a condition that pregnant women are generally diagnosed in the second half of their pregnancies. It is marked by elevated blood pressure and a high level of protein in the urine. When left untreated, it can progress to severe pre eclampsia (SPE), with complications of the lungs, kidney and liver, or can progress to eclampsia (Duley, , Meher, , Jones, 2013)Eclampsia is defined as the development of convulsions or coma in a woman with Pre-eclampsia. Among pregnant women worldwide 7-15% develops PE and approximately 1-2% develops eclampsia (Dolea, AbouZahr, 2003) Hypertensive disorders, which include PE/E, represent a significant proportion of maternal deaths worldwide.

Such deaths account 9.1%, 9.1% and 25.7% in Sub-Saharan Africa, South Asia, and Latin America respectively (Ton, et al 2019) Casefatality rates are significantly higher in less developed countries relative to more

¹ Assistant Professor Of Obstetrics &Gynecological Nursing, Faculty Of Applied Medical Sciences, Nursing department, Al-baha University Kingdom of Saudi- Arabia).
² Assistant Professor of Community Health Nursing, Faculty of Nursing, the National Ribat University Sudan). E-mail: rosalhalil307@yahoo.com
³ Assistant Professor of Medical Surgical Nursing, Faculty of Nursing Sciences Omdurman Islamic University Sudan).
⁴ Faculty of Applied Medical Sciences, Nursing department, Al-baha University Kingdom of Saudi- Arabia.
⁵ Dr Sulaiman Alhabib hospital
developed countries, ranging from 26.3% in South Africa to 1.8% in the United Kingdom.(Rabiu, et al 2018).Nepal Maternal Mortality and Morbidity Study 2008-2009 showed that PE/E has increased from 14% in 1998 to 21% in 2008.

It stated as the second most common cause of maternal mortality (Baral, et al 2010) Some studies were conducted in various hospitals of Nepal. The incidence of eclampsia was found 0.29% in Paropakar Maternity and Women’s Hospital(Choudhary, 2003) while in Koshi Zonal Hospital, pre-eclampsia, severe pre-eclampsia and eclampsia were found to be 0.7%, 0.3% and 1.3% respectively(Thapa, 2008). For most cases of SPE, eclampsia can be prevented by introducing MgSO4 an immediately initiating labor. In mother’s with SPE, MgSO4 was found to reduce the occurrence of eclampsia by more than 50% and maternal deaths by 46%.This is the national standard drug for treatment of SPE/E in Nepal(Warriner, et al 2011).and also listed to the Essential Drugs List(Poudel, et al 2009). In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of MgSO4. Intravenously, a dose of 4 to 5 g in 250 ml of 5% Dextrose Injection, 0.9% Sodium Chloride Injection may be infused. Simultaneously, intramuscular doses of up to 10 g (5 g in each buttock) are given.(Kaur, et al 2013)A potential concern for magnesium sulphate therapy is the risk of side effects which could increase with the duration of treatment especially if there are challenges in clinical monitoring of the patients. The therapeutic range of magnesium in plasma is 1.7 - 3.5 mmol/L. When there is increase in this level intoxication occurs resulting in magnesium intoxication. These include flushing, sweating, hypotension, flaccid paralysis, hypothermia, circulatory collapse, sinoatrial and atrioventricular blockade, cardiac and central nervous system depression proceeding to respiratory paralysis.

Hypocalcaemia with signs of tetany secondary to Magnesium Sulfate therapy for eclampsia has been reported.(Kaur, & Gainder, 2013)During the administration of magnesium sulphate the main nursing consideration is monitored hourly blood pressure, pulse, and respiratory rate. Magnesium sulfate affects the central nervous system of the mother. So as a part of normal care includes checking the mother's reflexes. If too much magnesium sulfate is given, the women reflexes will be slowed. Patellar reflexes are usually checked about every 1 to 4 hours. One hourly urine measures, four hourly testing of urinary protein.(Khan, Wojdyla, Say, Gülmezoglu,., & Van Look, 2006)Maternal mortality in the developing world is receiving increasing attention in recent years and significantly it is a key emphasis of the Millennium Development Goals (MDGs)(Nyamtema, Urassa, & van Roosmalen, 2011).The World Health Organization (WHO) reports that hemorrhage/bleeding, infections, unsafe abortions and eclampsia are common causes of maternal mortality especially in developing countries.(Langer, Villar,Tell, Kim, & Kennedy2008). Severe pre-eclampsia and eclampsia-related deaths are common causes of preventable maternal deaths by 99% of these deaths occurring in low and middle income countries. (Hogan, Foreman, Naghavi, Ahn, Wang, Makela, & Murray2010)Eclampsia is a major cause of maternal morbidity and mortality in Nigeria. It was reported to have contributed to 46.3% of maternal deaths in Kano State(Onah, Ikeako, & Iloabachie, 2006).And 43% of maternal deaths in Jigawa State. (Okereke, Ahonsi, Tukur, , Ishaku, & (Oginni, 2012). These figures indicate remarkably high rates of maternal mortality with high contributions from eclampsia-related maternal deaths in northern Nigeria.

WHO has recommended the use of magnesium sulphate (MgSO4) as a safe and low-cost drug to manage severe pre-eclampsia and eclampsia cases.(Urassa, 2004).Studies have shown that the drug significantly lowers the possibility of seizures in women with severe pre-eclampsia or eclampsia, prevents progression from severe preeclampsia to eclampsia and generally lowers maternal mortality.(Langer, Villar, Tell, Kim, & Kennedy2008).

2. Materials and Methods

2.1. Study design: a descriptive – cross sectional hospital based study was used.
2.2. Setting: Bhari Teaching Hospital, Saad Abualla, and Omdurman Maternity Hospital, Khartoum State - Sudan.
2.3. Sample: Are50 nurses/nurse midwives, who are working in obstetrical wards all are enrolled in this study as total coverage.
2.4. Data collection technique and tools: structured interview questionnaire sheet was developed to assess the nurses/nurse midwives’ knowledge regarding Magnesium Sulfate administration to pre-eclamptic /eclamptic mother and parameters of monitoring the patient.
2.5. Data processing and statistical analysis: Data were analyzed by using Statistical Package for Social Sciences program (SPSS) and Microsoft office excel 2007 was used for data processing and statistical analysis.
2.6. Validity and Reliability of instruments: The instruments were pre-tested in the pilot study before final data collection for reliability.
2.7. Ethical consideration: Written approval from Research, Ethical Committees, general medical directors of selected hospitals and verbal agree from the nurses are working in obstetric ward.
3. Results

3.1. Demographic Characteristics of the Study Sample:

The study participants were 50 nurses/nurse midwives who are working in obstetrical wards in Bhari Teaching Hospital, Saad Abualla, and the Omdurman Maternity Hospital.

3.1.1. Figure (1): Showed that, the frequency of socio-demographic characteristics of participants, years of experience of nurses/nurse midwives. Less than 5 years were (71.43%), from 5-10 years equal (16.33%), and more than 10 years had (12.24%).

3.1.2. Figure (2): showed levels of qualification of nurses/nurse midwives. (30.00%) are diploma nurses, while (50.00%) BSc nurses and (12.00%) are MSc nurses.

3.1.3. Figure (3): showed knowledge regarding the pharmacological group related to magnesium sulphate, Anticonvulsant (66%), Anticoagulant (2%), both of them (4%), don’t know (16%), and all of them (12%).

3.2. Knowledge and awareness of participants’ about magnesium sulphate:

3.2.1. Figure (4): illustrated the presence of participants’ knowledge regarding indication of magnesium sulfate. Preeclampsia (6%), eclampsia result (46%), both of them (20%), don’t know (24%), all of them (4%). This was statistically insignificant with experience (years) (P > 0.05) Table (1) and professional qualification Table (2).

3.2.2. Figure (5): illustrated the percentage of participants’ knowledge regarding the route of administration of MgSO4. Intramuscular (6%), intravenous (84%), subcutaneous (4%), don’t know (2%), all of them (4%). This was statistically insignificant with experience (years) (P > 0.05) Table (1) and professional qualification Table (2).

3.2.3. Figure (6): showed knowledge regarding the side effect of magnesium sulfate participants’ response was Headache (20%), edema (14%), visual disturbances (14%), epigastria pain (10%), don’t know (16%), all of them (26%). This was statistically insignificant with a professional qualification (P > 0.05) Table (2).

3.2.4. Figure (7): showed knowledge regarding the signs and symptom of toxicity participants’ response were Sweating (14%), depressed reflexes (14%), circulatory collapse (22%), don’t know (6%), all of them (24%). This was statistically insignificant with experience (years) (P > 0.05) Table (1) and professional qualification Table (2).

3.2.5. Figure (8): showed knowledge of Participants regarding the antidote of MgSO4. Calcium gluconate (50%), potassium chloride (16%), don’t know (30%), all of them (4%). This was statistically significant with experience (years) (P < 0.05) Table (1) and insignificant with professional qualification Table (2).

3.2.6. Figure (9): illustrated the percent of participants’ knowledge regarding the main nursing considerations for monitoring. Monitoring hourly blood pressure, pulse and respiratory rate (52%). One hourly urine measures (6%). Four hourly testing of urinary protein (2%). Don’t know (12%). All of the above (28%). This was statistically insignificant with experience (years) (P > 0.05) Table (1) and professional qualification Table (2).

3.3. Table (1): Showed the relationship between the knowledge of nurses/nurse midwives’ and their experience=50

| Pharmacological Group Related to Magnesium Sulphate | Experience (years) | Knowledge | P-value |
|---------------------------------------------------|--------------------|-----------|---------|
| Anticonvulsant                                    | <5 years | 7 | 4 | 32 | Fair | .908 |
|                                                    | 5-10 years | 14 | 8 | 66.7% | |
|                                                    | >10 years  | 8 | 8 | 69.9% | |
| Indications of Magnesium Sulphate                 | Both of them    | 17 | 6 | 3 | Fair | .189 |
|                                                    | %Total         | 34.7% | 12.2% | 6.1% | 53.1% |
| Maintenance Dose of Magnesium Sulphate            | 24 Mg           | 18 | 4 | 1 | Poor | .310 |
|                                                    | %Total         | 37.5% | 8.3% | 2.1% | 47.9% |
| Routes of Administration of MgSO4                 | All of them    | 33 | 7 | 6 | Good | .359 |
|                                                    | %Total         | 69.9% | 14.6% | 12.5% | 97.9% |
| The Side Effects of Magnesium Sulphate            | All of them    | 31 | 7 | 5 | Good | .450 |
|                                                    | %Total         | 66.6% | 14.6% | 6.2% | 85.4% |
| Signs and Symptom of Toxicity                     | All of them    | 32 | 7 | 6 | Good | .357 |
|                                                    | %Total         | 66.6% | 14.6% | 12.5% | 93.8% |
| The Antidote of Magnesium Sulphate                | Calcium Gluconate| 21 | 4 | 0 | Fair | .008 |
|                                                    | %Total         | 43.8% | 8.3% | .0% | 52.1% |
| Main Nursing Consideration for Monitoring         | All of them    | 30 | 7 | 5 | Good | .145 |
|                                                    | %Total         | 73.8% | 14.9% | 11.6% | 88.4% |
3.4. Table (2): Showed the relationship between the knowledge of nurses/nurse midwives’ and their professional qualification

Table (2): Showed the relationship between the knowledge of nurses/nurse midwives’ and their professional qualification: N=50.

| Item                                         | Option          | Professional Qualification | Total | Knowledge | P-value |
|-----------------------------------------------|-----------------|-----------------------------|-------|-----------|---------|
| Pharmacological group related to magnesium sulphate | Both of them    | Diploma nurse B.Sc(N) M.Sc(N) Total Knowledge P-value |       | 2         | 4.1%    |
| Indications of magnesium sulphate             | Both of them    | 8 17 2 27 Fair .218        |       |           |         |
| The maintenance dose of magnesium sulphate   | 24 Mg           | 4 14 5 23 Poor .038        |       |           |         |
| The routes of administration of MgSO4        | All of them     | 18 24 6 48 Good 384        |       |           |         |
| The side effects of magnesium sulphate       | All of them     | 14 23 4 41 Good .656       |       |           |         |
| Signs and symptom of toxicity                | All of them     | 17 24 5 46 Good .077       |       |           |         |
| The antidote of magnesium sulphate           | Calcium gluconate | 8 13 4 25 .780            |       |           |         |
| Main nursing consideration for monitoring    | All of them     | 16 21 6 43 Good .490       |       |           |         |

Figure (1): Showed years of experience of nurses/nurse midwives.

Figure (2): Showed level of qualification of nurses/nurse midwives.
Figure (3): Showed knowledge regarding the pharmacological group related to magnesium sulphate

Figure (4): Showed knowledge regarding indication of magnesium sulphate

Figure (5): Showed knowledge regarding the route of administration of MgSO4
Figure (6): Showed knowledge regarding the side effect of magnesium sulphate

Figure (7): Showed knowledge regarding the signs and symptom of toxicity

Figure (8): Showed knowledge regarding the antidote of MgSO4
4. Discussion

This study identified gaps in the knowledge of nurses/nurse midwives about Magnesium Sulphate, including administration and parameters of monitoring the patient. Magnesium sulphate has been used in obstetrics with good results, inhibiting premature labor and in the treatment of eclampsia-associated seizures.

A potential concern for magnesium sulphate therapy is the risk of side effects which could increase with the duration of treatment, especially if there are challenges in clinical monitoring of the patients (Okereke, Ahonsi, Ishaku, & Oginni, 2012). The majority of deaths due to preeclampsia and eclampsia can be avoided through the management of complications by effective and timely care to the women (Urassa, 2004). With nurse's help, we can drive awareness, advance our scientific understanding and medical practices, and help create a world where preeclampsia and hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies (Langer, Villar, Tell, Kim, & Kennedy, 2008).

The general objective of this study was to assess the current knowledge regarding the Magnesium Sulphate administration to pre-eclamptic/eclamptic mothers among nurses/nurse midwives working at Bhari Teaching Hospital, Saad Abualla, and Omdurman Maternity Hospital Khartoum State, Sudan. More than seventy percent of the participants (71.43%) had their experience is less than 5 years, this is not similar to study done in Ribat University Hospital, where 60% of the participants had more than 5 years in the obstetrics and gynecology department. More than half of participants were aware about recommended drug for controlling convulsion (66%), this finding was consistent with study conducted in Laquintinie hospital (2014) where nurses saw that magnesium sulphate is the best drug used to control fits or convulsion (Ramsey, Carline, Inui, Larson, LoGerfo, Norcini, & Wenrich, 1991). Also more than half of participants in this study were knowledgeable about the indication of magnesium sulphate (54%), but in a study done by Baljit Kaur all the subjects were knowledgeable about the indication of magnesium sulfate (Kaur, Rana, & Gainder, 2013). There are only two percent of the participants did not have knowledge about the route of administration of magnesium sulphate this is contrast to finding of a study done by Ramadurgin India society (2016). Where few of staff nurses had personal experience to administering magnesium sulfate, and they were unaware of appropriate routes and dosages (Ramadurg, Vidler, Charanthimath, Katageri, Bellad, Mallapur, & Qureshi, 2016). When twenty four percent of the respondents knew the signs and symptom of magnesium sulphate toxicity. Our finding is lower than the finding of another study done by Bangladesh society (2016) which indicated 61.9%. On the basis of the findings of the present study the knowledge of participants regarding the antidote of MgSO4 (Calcium gluconate) (50%), is higher than result of study done by Jamilu in Nigeria where finding is 16.8. This study reveals that most participants were not knowledgeable on prevention of toxicity (Monitoring hourly blood pressure, pulse and respiratory rate, One hourly urine measures. Four hourly testing of urinary protein) of magnesium sulphate, this is comparable to study done by Rahma Jaruf (2013) at Mnazi Mmoja Hospital, Zanzibar, which indicated 93% of nurse-midwives were not knowledgeable on monitoring of toxicity of magnesium sulfate (Affar, R. J. (2013)).

Acknowledgements

The authors would like to extend their thanks and appreciations to all participants who voluntarily participated in the study.
References

Affar, R. J. (2013). Knowledge and skills on managing eclampsia among nurse-midwives working at Marezimujo hospital, Unguja Zanzibar (Doctoral dissertation, Muhimbili University of Health and Allied Sciences.

Baral, Y. R., Lyons, K., Skinner, J. V. T. E., & Van Teijlingen, E. R. (2010). Determinants of skilled birth attendants for delivery in Nepal. *Kathmandu University Medical Journal, 8*(3), 325-332.

Choudhary, P. (2003). Eclampsia: a hospital based retrospective study. *Kathmandu University medical journal (KUMJ), 1*(4), 237-241.

Duley, L., Meher, S., & Jones, L. (2013). Drugs for treatment of very high blood pressure during pregnancy. *Cochrane Database of Systematic Reviews, (7)*

Dolea, C., & AbouZahr, C. (2003). Global burden of hypertensive disorders of pregnancy in the year 2000. *GBD 2000 Working Paper, World Health Organization, Geneva.* http://www.who.int/evidence/bod.. 2003b.“Global Burden of Obstructed Labor in the Year 2000.” GBD 2000 Working Paper, World Health Organization, Geneva. http://www.who.int/evidence/bod.

Ekele, B. A., Muhammed, D., Bello, I. N., & Namadina, I. M. (2009). Magnesium sulphate therapy in eclampsia: the Sokoto (ultra short) regimen. *BMC research notes, 2*(1), 165.

Hogan, M. C., Foreman, K. J., Naghavi, M., Ahn, S. Y., Wang, M., Makela, S. M., ... & Murray, C. J. (2010). Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. *The lancet, 375*(9726), 1609-1623.

Kaur, B., Rana, A. K., & Gainder, S. (2013). Operationalization of Nursing Assessment sheet for administration of Magnesium Sulphate. *Nursing and Midwifery Research, 9*(3), 118.

Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M., & Van Look, P. F. (2006). WHO analysis of causes of maternal death: a systematic review. *The lancet, 367*(9516), 1066-1074.

Langer, A., Villar, J., Tell, K., Kim, T., & Kennedy, S. (2008). Reducing eclampsia-related deaths—a call to action. *The Lancet, 371*(9614), 705-706.

Nyamtema, A. S., Urassa, D. P., & van Roosmalen, J. (2011). Maternal health interventions in resource limited countries: a systematic review of packages, impacts and factors for change. *BMC pregnancy and childbirth, 11*(1), 30.

Okereke, E., Ahonsi, B., Tukur, J., Ishaku, S. M., & Oginni, A. B. (2012). Benefits of using magnesium sulphate (MgSO 4) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria. *BMC research notes, 5*(1), 421.

Onah, H. E., Ikeako, L. C., & Iloabachie, G. C. (2006). Factors associated with the use of maternity services in Enugu, southeastern Nigeria. *Social science & medicine, 63*(7), 1870-1878.

Poudel, A., Khanal, S., Alam, K. A. D. I. R., & Palaian, S. (2009). Perception of Nepalese community pharmacists towards patient counseling and continuing pharmacy education program: A multicentric study. *J ClinDiag Res, 3*(2), 1408-1413.

Rabiu, K. A., Adewunmi, A. A., Ottun, T. A., Akinlusi, F. M., Adebano, A. A., & Alausa, T. G. (2018). risk factors for maternal mortality associated with eclampsia presenting at a nigerian tertiary hospital. International journal of women's health, 10, 715.

Ramsey, P. G., Carline, J. D., Inui, T. S., Larson, E. B., LoGerfo, J. P., Norcini, J. J., & Wenrich, M. D. (1991). Changes over time in the knowledge base of practicing internists. *Jama, 266*(8), 1103-1107.

Ton, T. G., Bennett, M. V., Incerti, D., Peneva, D., Druzin, M., Stevens, W., ... & Lee, H. C. (2019). Maternal and Infant Adverse Outcomes Associated with Mild and Severe Preeclampsia during the First Year after Delivery in the United States. American journal of perinatology.

Tukur, J., Ishaku, M., Ahonsi, B., Oginni, A., & Adoyi, G. (2016). Training-of-trainers of nurses and midwives as a strategy for the reduction of eclampsia-related maternal mortality in Nigeria. *Sabel Medical Journal, 19*(2), 63-63.

Thapa, K., & Jha, R. (2008). Magnesium sulphate: a life saving drug. *Journal of Nepal Medical Association, 47*(171).

Warriner, I. K., Wang, D., Huong, N. M., Thapa, K., Tamang, A., Shah, I., ... & Meirik, O. (2011). Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. *The Lancet, 377*(9772), 1155-1161.